Case Reports

Leading breakthrough case studies on psychedelics and beyond

 

  • Ketamine

    Dissociative anesthetic; C13H16ClNO; Special K, Blind Squid, Cat Valium, Green, Jet, K, K-Hold, Kay, Super Acid, Vitamin K

  • Psilocybin

    Classic hallucinogen; C12H17N2O4P; Magic Mushrooms, Shrooms, Mushies, Boomers, Alice, Caps, Tweezes

  • LSD

    Classic hallucinogen; C20H25N3O; Acid, Lucy, Tabs, Blotter, Dots, Sugar Cubes, Yellow Sunshine, Window Pane

  • Mescaline

    Classic hallucinogen; C11H17NO3·HCl; Big Chief, Blue Caps, Buttons, Cactus, Mescal, Moon, San Pedro, Topi

  • MDMA

    Empathogen-entactogen; C11H15NO2; Ecstasy, Molly, XTC, E, X, Beans, Adams, Candy, Clarity, Dancing Shoes, Rolls, Eve

5-MeO-DMT Therapy for Post-Traumatic Stress Disorder: A Longitudinal Case Study

Anya Ragnhildstveit; Ryan Khan; Lynnette Averill, PhD

This is a longitudinal case study on 5-MeO-DMT therapy for chronic refractory PTSD, among a 23-year-old female. A single vaporized dose, administered via inhalation, led to clinically significant improvements in PTSD, with next-day effects. This was sustained at 1-, 3-, 6-, and 12-months follow-up. The patient endured a strong mystical experience, hypothesized to underly 5-MeO-DMT’s therapeutic activity. No drug-related serious adverse events were reported, nor hemodynamic changes in blood pressure, heart rate, or oxygen saturation. These findings highlight the therapeutic potential of 5-MeO-DMT for PTSD. Future research is warranted.

COLLABORATIONS: Inquiries to collaborate on this study are welcomed by researchers actively investigating 5-MeO-DMT for mental health. Email Anya Ragnhildstveit directly.

RESEARCH NOTICE: This study is exempt from ethics review. According to the Institutional Review Board at Baylor College of Medicine: “Case reports or case series describing interesting observations on three or fewer patients do not meet the definition of research as a systematic investigation designed to contribute to generalizable knowledge. Therefore the IRB does not review or approve such reports”.

LSD Therapy for Generalized Anxiety Disorder: A Real-World Case Report

Anya Ragnhildstveit; Naz Uzun; Senior Investigator TBD

This clinical trial will investigate changes in functional brain network organization among healthy volunteers dosed with psilocybin. State-of-the-art, precision neuroscience techniques and rigorous data collection measures will be utilized, including: a) resting state functional magnetic resonance imaging (rs-fMRI) and electroencephalography (EEG), b) blood sampling to detect presence and change in psilocybin as well as other potential biomarkers of interest, and c) valid scales to assess participants’ psychedelic experience, emotions, and creativity, among other constructs.

NOTICE: This study has NOT gained ethics approval. It is preparing for review by the Duke Health Institutional Review Board to ensure the protection of human research subjects. Participants at NOT being recruited at this time.

MDMA-Assisted Therapy for Bulimia Nervosa: A Longitudinal Case Study

Anya Ragnhildstveit; Senior Investigator TBD

This randomized, survey-based study will explore stigma against the notion of receiving at-home psychedelic therapy from mental health chatbots compared to humans. This is rooted in the intuition that AIs are likely not viewed as ‘true’ therapists capable of satisfying concrete features and their abstract values, such as presence, trust, and empathy - key competencies of psychedelic therapists. Results will guide discussions on emerging, digital-based solutions with potential to increase access to care in the field.

NOTICE: This study has been approved by the Duke Health Institutional Review Board (Protocol ID: #2023-0002). Participants are being recruited at this time, primarily through Amazon’s Mechanical Turk and Prolific subject pools. Inquire for details.